These Analysts Boost Their Forecasts On Medtronic After Upbeat Q1 Earnings

Core Insights - Medtronic plc reported better-than-expected earnings for Q1 2026, with sales of $8.58 billion, exceeding the consensus estimate of $8.38 billion, representing an 8.4% year-over-year increase and 4.8% organic growth [1] - The company announced key board appointments, naming John Groetelaars and Bill Jellison as independent directors [1] Financial Performance - Adjusted earnings per share for Q1 2026 were $1.26, surpassing expectations of $1.23 [1] - Medtronic reiterated its fiscal year 2026 organic revenue growth guidance of 5% and revised its reported revenue growth forecast from 4.8%-5.1% to 6.5%-6.8% [2] - Sales guidance for fiscal 2026 was raised from $35.15 billion-$35.25 billion to $35.72 billion-$35.82 billion, compared to the consensus of $35.32 billion [2] Market Reaction - Following the earnings announcement, Medtronic shares increased by 4.4%, trading at $93.84 [3] - Analysts adjusted their price targets for Medtronic, with Bernstein analyst Lee Hambright raising the target from $97 to $98 and Baird analyst David Rescott increasing it from $94 to $96 [8]